In pre-clinical studies, targeting HER2 in a glioblastoma multiforme (GBM) cell line resulted in the emergence of HER2-null tumor cells that maintained expression of non-targeted tumor-associated antigens. This evidence concerns the gene ERBB2 and glioblastoma.